Susan Wiviott Net Worth

The estimated Net Worth of Susan Wiviott is at least $58.6 ezer dollars as of 11 August 2017. Susan Wiviott owns over 2,000 units of Kadmon Inc stock worth over $58,596 and over the last 8 years Susan sold KDMN stock worth over $0.

Susan Wiviott KDMN stock SEC Form 4 insiders trading

Susan has made over 1 trades of the Kadmon Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Susan bought 2,000 units of KDMN stock worth $4,440 on 11 August 2017.

The largest trade Susan's ever made was buying 2,000 units of Kadmon Inc stock on 11 August 2017 worth over $4,440. On average, Susan trades about 400 units every 0 days since 2016. As of 11 August 2017 Susan still owns at least 6,168 units of Kadmon Inc stock.

You can see the complete history of Susan Wiviott stock trades at the bottom of the page.

What's Susan Wiviott's mailing address?

Susan's mailing address filed with the SEC is C/O KADMON HOLDINGS, INC., 450 E. 29TH STREET, NEW YORK, NY, 10016.

Insiders trading at Kadmon Inc

Over the last 8 years, insiders at Kadmon Inc have traded over $7,020,661 worth of Kadmon Inc stock and bought 7,084,916 units worth $54,943,934 . The most active insiders traders include Advisors Llcperceptive Life..., Asset Management Lp Golden ... és Daniel S Third Point Llc Loeb. On average, Kadmon Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,948,175. The most recent stock trade was executed by Harlan Waksal on 13 March 2020, trading 16,000 units of KDMN stock currently worth $46,880.

What does Kadmon Inc do?

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Complete history of Susan Wiviott stock trades at Kadmon Inc

Kadmon Inc executives and stock owners

Kadmon Inc executives and other stock owners filed with the SEC include:

• Harlan Waksal,
  President, Chief Executive Officer, Director
• Steven Meehan,
  Chief Financial Officer, Executive Vice President
• Gregory Moss,
  Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
• Dr. Harlan W. Waksal,
  Pres, CEO & Director
• Gregory S. Moss Esq.,
  Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Arthur Kirsch,
  Independent Director
• David Cohen,
  Independent Director
• Cynthia Schwalm,
  Independent Director
• Eugene Bauer,
  Independent Director
• Tasos Konidaris,
  Non-Executive Independent Chairman of the Board
• Ellen Cavaleri,
  IR Contact Officer
• Nancy Miller-Rich,
  Director
• John Ryan,
  Executive Vice President, Chief Medical Officer
• Dr. Simon Cooper,
  Sr. VP & Chief Medical Officer
• Haya Taitel M.S., R.Ph.,
  Sr. VP & Chief Commercial Officer
• Sanjay Aggarwal,
  Sr. VP of Clinical Devel.
• Kyle Carver,
  Sr. VP, Chief Accounting Officer & Controller
• Charles Darder,
  Principle Accounting Officer
• Asset Management Lp Golden ...,
  
• D. Dixon Boardman,
  
• Konstantin Poukalov,
  EVP, Chief Financial Officer
• Alexandria Forbes,
  
• Andrew B Cohen,
  
• I, Llc Kadmon,
  
• Susan Wiviott,
  
• Shengda Zan,
  
• Thomas E Shenk,
  
• Steven N. Gordon,
  Exec VP, GC, Chief Admin, Comp
• Lawrence Kenneth Cohen,
  Exec. VP, Business Develop.
• Daniel S Third Point Llc Loeb,
  
• Bart M Schwartz,
  
• Advisors Llcperceptive Life...,
  
• Kyle Carver,
  SVP, CAO, Controller
• Cynthia Louise Flowers,
  Director